MY148258A - Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments - Google Patents

Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments

Info

Publication number
MY148258A
MY148258A MYPI20084472A MYPI20084472A MY148258A MY 148258 A MY148258 A MY 148258A MY PI20084472 A MYPI20084472 A MY PI20084472A MY PI20084472 A MYPI20084472 A MY PI20084472A MY 148258 A MY148258 A MY 148258A
Authority
MY
Malaysia
Prior art keywords
phenylamino
carboxylic acids
medicaments
production
substituted carboxylic
Prior art date
Application number
MYPI20084472A
Other languages
English (en)
Inventor
Defossa Elisabeth
Follmann Markus
Klabunde Thomas
Drosou Viktoria
Hessler Gerhard
Stengelin Siegfried
Haschke Guido
Herling Andreas
Bartoschek Stefan
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MY148258A publication Critical patent/MY148258A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20084472A 2006-05-11 2007-04-30 Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments MY148258A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MY148258A true MY148258A (en) 2013-03-29

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20084472A MY148258A (en) 2006-05-11 2007-04-30 Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments

Country Status (30)

Country Link
US (2) US20090149519A1 (enExample)
EP (1) EP2024347B1 (enExample)
JP (1) JP2009536629A (enExample)
KR (1) KR20090006846A (enExample)
CN (1) CN101437805B (enExample)
AR (1) AR060990A1 (enExample)
AU (1) AU2007250213B2 (enExample)
BR (1) BRPI0711448A2 (enExample)
CA (1) CA2651660A1 (enExample)
CO (1) CO6241107A2 (enExample)
CY (1) CY1113177T1 (enExample)
DE (1) DE102006021878A1 (enExample)
DK (1) DK2024347T3 (enExample)
ES (1) ES2391203T3 (enExample)
HR (1) HRP20120829T1 (enExample)
IL (1) IL195179A0 (enExample)
MA (1) MA30402B1 (enExample)
MX (1) MX2008014102A (enExample)
MY (1) MY148258A (enExample)
NO (1) NO20085068L (enExample)
NZ (1) NZ572692A (enExample)
PL (1) PL2024347T3 (enExample)
PT (1) PT2024347E (enExample)
RS (1) RS52450B (enExample)
RU (1) RU2434003C2 (enExample)
SI (1) SI2024347T1 (enExample)
TW (1) TW200812987A (enExample)
UY (1) UY30338A1 (enExample)
WO (1) WO2007131622A1 (enExample)
ZA (1) ZA200808490B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
US8716283B2 (en) 2007-11-07 2014-05-06 University Of Massachusetts Type III secretion inhibitors, analogs and uses thereof
AU2009220163B2 (en) 2008-03-06 2011-10-06 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
JP5551707B2 (ja) 2008-10-15 2014-07-16 アムジエン・インコーポレーテツド スピロ環ｇｐｒ４０調節因子
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013039140A1 (ja) * 2011-09-14 2013-03-21 第一三共株式会社 縮合へテロ環誘導体
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
SG11202107080VA (en) 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491863A (en) * 1973-10-23 1977-11-16 Lilly Industries Ltd 2,5-or 2,6-disubstituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5559127A (en) * 1992-10-14 1996-09-24 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69816280T2 (de) * 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
JP2002521375A (ja) * 1998-07-23 2002-07-16 アストラゼネカ アクチエボラーク 化合物
DK1153017T3 (da) * 1999-02-16 2006-07-17 Aventis Pharma Ltd Bicykliske forbindelser og deres anvendelse som integrinreceptorligander
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
JP3786203B2 (ja) * 2000-11-04 2006-06-14 アベンティス・フアーマ・リミテッド 置換アルカン酸
US7157487B2 (en) * 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Also Published As

Publication number Publication date
UY30338A1 (es) 2008-01-02
WO2007131622A1 (de) 2007-11-22
CN101437805B (zh) 2012-05-30
AU2007250213A1 (en) 2007-11-22
CA2651660A1 (en) 2007-11-22
ZA200808490B (en) 2009-10-28
US20130303578A1 (en) 2013-11-14
CN101437805A (zh) 2009-05-20
EP2024347B1 (de) 2012-08-01
US20090149519A1 (en) 2009-06-11
NZ572692A (en) 2011-03-31
PT2024347E (pt) 2012-10-09
KR20090006846A (ko) 2009-01-15
IL195179A0 (en) 2009-08-03
SI2024347T1 (sl) 2012-11-30
BRPI0711448A2 (pt) 2011-11-08
PL2024347T3 (pl) 2013-01-31
HK1131978A1 (en) 2010-02-12
EP2024347A1 (de) 2009-02-18
ES2391203T3 (es) 2012-11-22
MX2008014102A (es) 2008-11-14
DK2024347T3 (da) 2012-10-29
AU2007250213B2 (en) 2013-04-11
US8748465B2 (en) 2014-06-10
HRP20120829T1 (hr) 2012-11-30
RS52450B (sr) 2013-02-28
RU2008148838A (ru) 2010-06-20
TW200812987A (en) 2008-03-16
MA30402B1 (fr) 2009-05-04
AR060990A1 (es) 2008-07-30
JP2009536629A (ja) 2009-10-15
NO20085068L (no) 2009-02-04
CO6241107A2 (es) 2011-01-20
RU2434003C2 (ru) 2011-11-20
DE102006021878A1 (de) 2007-11-15
CY1113177T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MY149731A (en) Compounds
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
TN2011000199A1 (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
MX383551B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
IN2012DN01292A (enExample)
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2011009533A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10) -dien-11-ethinylphenyl-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
GEP20125526B (en) Drug active in neuropathic pain
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
UA96951C2 (ru) ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ КАК ЛЕКАРСТВЕННЫХ СРЕДСТВ